

Supplemental Appendix

	1L				Post-1L							
	Utilization over the 1-year period after initiating 1L therapy [1]				Utilization over the 1-year period after completing 1L therapy in patients who have a complete/very good partial hematologic response [1]				Utilization over the 1-year period after completing 1L therapy in patients who have a partial/no hematologic response, or the 1-year period after relapse [1]			
	Mayo 2012 stage 1/2 [2, 3]		Mayo 2012 stage 3/4		Without cardiac involvement		With cardiac involvement [4]		Without cardiac involvement		With cardiac involvement [4]	
	Renal Involvement				Renal Involvement				Renal Involvement			
	No	Yes	No	Yes	No	Yes	No	Yes	No	Yes	No	Yes
How many of the following tests does this type of patient have per year?												
Serum free light chains, serum protein electrophoresis, and serum immunofixation	12.0	12.0	12.0	12.0	4.0	4.0	6.0	6.0	12.0	12.0	12.0	12.0
Troponin and NT-proBNP	4.0	4.0	6.0	9.0	2.0	2.0	4.0	4.0	3.5	3.5	6.0	7.0
EKG	2.0	2.0	3.0	3.5	1.0	1.0	1.5	2.0	1.0	1.0	2.5	2.5
Echocardiogram	1.0	1.0	2.0	2.0	1.0	1.0	2.0	2.0	1.0	1.0	2.0	2.0
How many patients out of 100 would be treated with the following in 1 year? [5]												
Daratumumab (dara) containing regimen	80.0	90.0	92.5	92.5	20.0	25.0	42.5	42.5	47.5	50.0	50.0	50.0
Other non-dara containing chemotherapy	12.5	11.0	12.5	12.5	7.5	10.0	10.0	10.0	55.0	55.0	60.0	60.0
Hematopoietic stem-cell transplantation	30.0	30.0	5.0	1.0	10.0	10.0	3.0	0.5	22.5	20.0	10.0	5.0
How many patients out of 100 would have the following in 1 year?												
Bone marrow biopsy/aspiration	25.0	25.0	25.0	22.5	3.5	5.0	5.0	5.0	50.0	50.0	50.0	50.0
Pacemaker or Implantable Cardioverter Defibrillator (ICD) placement	1.0	1.5	12.5	15.0	0.0	0.0	7.5	10.0	0.0	0.0	10.0	10.5
Heart transplant	0.0	0.0	1.0	0.5	0.0	0.0	1.5	0.5	0.0	0.0	2.5	1.5
Kidney transplant	0.0	0.0	0.0	0.0	0.0	4.0	0.0	1.0	0.0	0.0	0.0	0.0
Carpal tunnel syndrome release	3.0	5.0	2.0	4.0	1.0	5.0	1.0	2.0	1.5	5.0	2.0	4.0
Initiation of chronic dialysis	0.0	5.0	3.0	7.0	0.0	5.0	1.0	7.0	1.0	10.0	1.5	10.0
Any amyloidosis related inpatient admissions	5.0	12.5	45.0	55.0	0.0	5.0	15.0	20.0	2.0	15.0	30.0	42.5
Two or more amyloidosis related inpatient admissions	3.5	5.0	27.5	37.5	0.0	2.5	10.0	10.0	1.0	6.0	15.0	20.0

Notes:

[1] May or may not have an organ response to their 1L treatments.

[2] During 1L, non-advanced patients were those with Mayo stages 1/2 while advanced were those with Mayo stages 3/4. Post-1L, non-advanced patients were those without cardiac involvement while advanced were those with cardiac involvement. Additional utilization values are provided in supplemental appendix.

[3] Revised Mayo 2012 model: stage 1 troponin ≥ 0.025 $\mu\text{g/L}$, NT-proBNP ≥ 1800 ng/L, dFLC ≥ 180 mg/L. For each stage, stage 1 is absence of any risk factors; stage 2 is presence of 1 risk factor; stage 3 is presence of 2 risk factors; and where applicable, stage 4 is all risk factors present.

[4] Elevated troponin and/or NT-proBNP.

[5] For each treatment, estimate the proportion of patients who are on this regimen regardless of the other treatments they may also be on.